瑞舒伐他汀及唑来膦酸联合PVP术治疗老年压缩性骨折疗效观察  

Efficacy of rosuvastatin and zoledronic acid combined with PVP surgery in the treatment of senile compression fractures

作　　者：孙思鑫 朱志军[1] 孔德群[1] 刘宏鸣[1] SUN Si-xin;ZHU Zhi-jun;KONG De-qun;LIU Hong-ming(Department of Orthopedics,People's Hospital of Taixing City,Taizhou 225400,Jiangsu,CHINA)

机构地区：[1]泰兴市人民医院骨科,江苏泰州225400

出　　处：《海南医学》2021年第24期3194-3197,共4页Hainan Medical Journal

摘　　要：目的观察瑞舒伐他汀及唑来膦酸联合经皮椎体成形术(PVP)治疗老年压缩性骨折的疗效。方法选择2019年1月至2020年3月泰兴市人民医院收治的65例老年压缩性骨折患者为研究对象。根据随机单双数法将患者分为对照组32例和联合组33例。对照组患者使用PVP术治疗,联合组在对照组治疗的基础上联合使用瑞舒伐他汀及唑来膦酸治疗。12个月后,比较两组患者的临床疗效、骨密度、Oswestry功能障碍指数、视觉模拟评分(VAS)、血骨钙素(BGP)、I型胶原交联羧基端肽(CTXI)、I型胶原交联氨基端肽(NTXI)以及骨特异性碱性磷酸酶(BAP)水平。结果联合组患者的治疗总有效率为96.97%,明显高于对照组的78.13%,差异有统计学意义(P<0.05);治疗前,两组患者的骨密度、Oswestry指数与VAS评分比较差异均无统计学意义(P>0.05),治疗后,联合组患者的骨密度为(0.55±0.14)g/cm^(3),明显高于对照组的(0.46±0.10)g/cm^(3),Oswestry指数为(21.25±3.08)分,明显低于对照组的(28.97±3.32)分,差异均有统计学意义(P<0.05);联合组患者治疗3个月和治疗12个月后的VAS评分分别为(4.66±1.25)分和(3.82±0.95)分,明显低于对照组的(6.53±1.64)分和(2.33±0.69)分,差异均有统计学意义(P<0.05);治疗后,联合组患者的BGP、CTXI、NTXI、BAP水平分别为(3.03±0.69)μg/L、(29.21±3.24)ng/L、(2.95±0.82)nmol/L、(13.79±4.68)μg/L,明显低于对照组的(6.37±1.84)μg/L、(42.01±5.08)ng/L、(4.14±0.78)nmol/L、(19.25±5.33)μg/L,差异均有统计学意义(P<0.05)。结论瑞舒伐他汀及唑来膦酸联合PVP术治疗老年压缩性骨折能明显改善患者的疼痛程度及功能障碍,降低骨代谢指标,临床治疗效果显著,值得推广应用。Objective To observe the efficacy of rosuvastatin and zoledronic acid combined with percutaneous vertebroplasty(PVP)in the treatment of senile compression fractures.Methods A total of 65 elderly patients with compression fractures who were treated in People’s Hospital of Taixing City from January 2019 to March 2020 were selected as the research objects.According to the random odd and even number method,the patients were divided into the control group(32 cases)and the combination group(33 cases).The control group was treated with PVP surgery,and the combination group was treated with rosuvastatin and zoledronic acid on the basis of the control group.The clinical efficacy,bone density,Oswestry dysfunction index,visual analogue scale(VAS),blood osteocalcin(BGP),type I collagen cross-linked carboxyl terminal peptide(CTXI),Diamino terminal peptide(NTXI),and bone-specific alkaline phosphatase(BAP)were compared between the two groups after 12 months.Results The total effective rate of the combination group was 96.97%,which was significantly higher than 78.13%of the control group(P<0.05);before treatment,the bone mineral density,Oswestry index,and VAS score showed no statistically significant difference between the combination group and the control group(P>0.05);after treatment,the bone density of the combined group were(0.55±0.14)g/cm^(3),which was significantly higher than(0.46±0.10)g/cm^(3) of the control group;Oswestry index was(21.25±3.08)points,which was significantly lower than(28.97±3.32)points of the control group;the VAS scores of the combination group after 3 months of treatment and 12 months of treatment were(4.66±1.25)points and(3.82±0.95)points,which were significantly lower than(6.53±1.64)points and(2.33±0.69)points of the control group(P<0.05);after treatment,the BGP,CTXI,NTXI,BAP of the combination group were(3.03±0.69)μg/L,(29.21±3.24)ng/L,(2.95±0.82)nmol/L,(13.79±4.68)μg/L,significantly lower than(6.37±1.84)μg/L,(42.01±5.08)ng/L,(4.14±0.78)nmol/L,(19.25±5.33)μg/L in the control gr

关 键 词：压缩性骨折 瑞舒伐他汀 唑来膦酸 经皮椎体成形术 老年 临床疗效 

分 类 号：R683[医药卫生—骨科学]